Who are Clopidogrel and Aspirin's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/clopidogrel-and-aspirin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Clopidogrel and Aspirin — Competitive Intelligence Brief

Clopidogrel and Aspirin (Clopidogrel and Aspirin) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dual antiplatelet agent (combination therapy). Area: Cardiovascular.

phase 3 Dual antiplatelet agent (combination therapy) P2Y12 receptor (clopidogrel); COX-1 (aspirin) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Clopidogrel and Aspirin (Clopidogrel and Aspirin) — Beijing Tiantan Hospital. Clopidogrel and aspirin work together as dual antiplatelet agents to prevent blood clots by inhibiting platelet aggregation through different pathways.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Clopidogrel and Aspirin TARGET	Clopidogrel and Aspirin	Beijing Tiantan Hospital	phase 3	Dual antiplatelet agent (combination therapy)	P2Y12 receptor (clopidogrel); COX-1 (aspirin)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dual antiplatelet agent (combination therapy) class)

Beijing Tiantan Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Clopidogrel and Aspirin — Competitive Intelligence Brief. https://druglandscape.com/ci/clopidogrel-and-aspirin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab